Physician profile
Marina Rocchi
NPI 1659669489
$2,268.95
in general payments reported to CMS, 2019-2025
19 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $470 · 2021: $196 · 2022: $198 · 2023: $241 · 2024: $352 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $403.69 | 2019-2025 | Precision 1, Acrysof Iq Panoptix Uv Iol, Rocklatan |
| Rxsight INC | $377.25 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $374.42 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.66 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $204.25 | 2019-2021 | |
| Allergan, INC. | $109.74 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $78.90 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $78.07 | 2021-2023 | |
| Maculogix, INC. | $59.14 | 2020 | |
| Dompe US, INC. | $58.58 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $49.55 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $47.50 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $45.02 | 2022-2023 | Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $37.56 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $34.01 | 2022-2025 | Scoutpro Osmolarity System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.40 | 2022 | |
| Oyster Point Pharma, INC. | $20.44 | 2024 | Tyrvaya |
| Coopervision INC. | $15.23 | 2022 | |
| Travere Therapeutics, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Rocchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.